- Conditions
- Pre-eclampsia, Pregnancy, Post Partum
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Condition Directory
Hypertension clinical trials
Directory of U.S. ClinicalTrials.gov public records for Hypertension. Browse Hypertension recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 7, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2192
Shown on this page
12
Current sort
Recently updated
Condition scope
Hypertension
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Hypertension studies are organized in the registry
“Hypertension” searches also surface pulmonary hypertension — a different disease with its own research community — so watch for “pulmonary” in titles when scanning results. The blood-pressure portfolio itself includes a high share of behavioral, dietary, and device studies alongside medication trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 49–60 of 2,192 matching trials for Hypertension.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Hypertension, Breakfast Skipper
- Interventions
- Early Time-Restricted Eating (eTRE)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- REGN22530
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Deerfield Beach, Florida
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
- Interventions
- Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group)
- Behavioral
- Lead sponsor
- Texas Southern University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- REGN13335, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Omaha, Nebraska + 1 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Placebo/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 133
- States / cities
- Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- selexipag (Uptravi)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Seattle, Washington
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Interventions
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
- Other · Drug
- Lead sponsor
- D. Walter Wray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Liver Cirrhosis
- Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
About this Hypertension clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Hypertension as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Hypertension.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Hypertension.